ACAT inhibition and amyloid beta reduction |
| |
Authors: | Raja Bhattacharyya Dora M. Kovacs |
| |
Affiliation: | Neurobiology of Disease Laboratory, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA |
| |
Abstract: | Alzheimer's disease (AD) is a devastating neurodegenerative disorder. Accumulation and deposition of the beta-amyloid (Aβ) peptide generated from its larger amyloid precursor protein (APP) is one of the pathophysiological hallmarks of AD. Intracellular cholesterol was shown to regulate Aβ production. Recent genetic and biochemical studies indicate that not only the amount, but also the distribution of intracellular cholesterol is critical to regulate Aβ generation. Acyl-coenzyme A: cholesterol acyl-transferase (ACAT) is a family of enzymes that regulates the cellular distribution of cholesterol by converting membrane cholesterol into hydrophobic cholesteryl esters for cholesterol storage and transport. Using pharmacological inhibitors and transgenic animal models, we and others have identified ACAT1 as a potential therapeutic target to lower Aβ generation and accumulation. Here we discuss data focusing on ACAT inhibition as an effective strategy for the prevention and treatment of AD. |
| |
Keywords: | AD, Alzheimer's disease Aβ, beta-Amyloid APP, Amyloid precursor protein ACAT, Acyl-coenzyme A: cholesterol acyl-transferase FC, free cholesterol CE, cholesteryl ester ER, endoplasmic reticulum BBB, blood&ndash brain barrier Tg, transgenic |
本文献已被 ScienceDirect 等数据库收录! |
|